{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T09:44:47Z","timestamp":1768383887017,"version":"3.49.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04246-9","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T07:46:25Z","timestamp":1765266385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated multi-omics analysis identifies DARS2, MRTO4, and MRPL37 as novel biomarkers and potential therapeutic targets for bladder cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Lei","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijie","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiliang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"4246_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"4246_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234\u201341. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033.","journal-title":"Eur Urol"},{"key":"4246_CR3","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.eururo.2020.09.006","volume":"78","author":"JY Teoh","year":"2020","unstructured":"Teoh JY, et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol. 2020;78:893\u2013906. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.006.","journal-title":"Eur Urol"},{"key":"4246_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010.","journal-title":"Eur Urol"},{"key":"4246_CR5","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/s0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, et al. Bladder cancer. Lancet. 2016;388:2796\u2013810. https:\/\/doi.org\/10.1016\/s0140-6736(16)30512-8.","journal-title":"Lancet"},{"key":"4246_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-022-00406-y","volume":"9","author":"YH Jin","year":"2022","unstructured":"Jin YH, et al. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Mil Med Res. 2022;9:44. https:\/\/doi.org\/10.1186\/s40779-022-00406-y.","journal-title":"Mil Med Res"},{"key":"4246_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/bju.14915","volume":"125","author":"J Taylor","year":"2020","unstructured":"Taylor J, Becher E, Steinberg GD. Update on the guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2020;125:197\u2013205. https:\/\/doi.org\/10.1111\/bju.14915.","journal-title":"BJU Int"},{"key":"4246_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/s1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312\u201322. https:\/\/doi.org\/10.1016\/s1470-2045(17)30065-7.","journal-title":"Lancet Oncol"},{"key":"4246_CR9","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/s1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22:919\u201330. https:\/\/doi.org\/10.1016\/s1470-2045(21)00147-9.","journal-title":"Lancet Oncol"},{"key":"4246_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/bju.14643","volume":"123","author":"E Doyle","year":"2019","unstructured":"Doyle E, et al. Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. BJU Int. 2019;123:947\u201358. https:\/\/doi.org\/10.1111\/bju.14643.","journal-title":"BJU Int"},{"key":"4246_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1481296","volume":"15","author":"T Yang","year":"2024","unstructured":"Yang T, et al. Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis. Front Immunol. 2024;15:1481296. https:\/\/doi.org\/10.3389\/fimmu.2024.1481296.","journal-title":"Front Immunol"},{"key":"4246_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.euf.2023.04.011","volume":"9","author":"F Davaro","year":"2023","unstructured":"Davaro F, Jain R, Li R. Immune checkpoint inhibitor toxicity management in non-muscle-invasive bladder cancer: what urologists need to know. Eur Urol Focus. 2023;9:579\u201381. https:\/\/doi.org\/10.1016\/j.euf.2023.04.011.","journal-title":"Eur Urol Focus"},{"key":"4246_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055.","journal-title":"Eur Urol"},{"key":"4246_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2174\/0115680096272663231121100515","volume":"24","author":"S Wan","year":"2024","unstructured":"Wan S, et al. Immunologic crosstalk of endoplasmic reticulum stress signaling in bladder cancer. Curr Cancer Drug Targets. 2024;24:701\u201319. https:\/\/doi.org\/10.2174\/0115680096272663231121100515.","journal-title":"Curr Cancer Drug Targets"},{"key":"4246_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ijrobp.2011.08.034","volume":"83","author":"MJ Zelefsky","year":"2012","unstructured":"Zelefsky MJ, et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83:953\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.08.034.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4246_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/genes15081036","author":"AJ Clark","year":"2024","unstructured":"Clark AJ, Lillard JW. A comprehensive review of bioinformatics tools for genomic biomarker discovery driving precision oncology. Genes. 2024. https:\/\/doi.org\/10.3390\/genes15081036.","journal-title":"Genes"},{"key":"4246_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559.","journal-title":"BMC Bioinformatics"},{"key":"4246_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1142\/s0219720005001375","volume":"3","author":"ME Futschik","year":"2005","unstructured":"Futschik ME, Carlisle B. Noise-robust soft clustering of gene expression time-course data. J Bioinform Comput Biol. 2005;3:965\u201388. https:\/\/doi.org\/10.1142\/s0219720005001375.","journal-title":"J Bioinform Comput Biol"},{"key":"4246_CR19","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41596-018-0103-9","volume":"14","author":"J Reimand","year":"2019","unstructured":"Reimand J, et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, cytoscape and enrichmentmap. Nat Protoc. 2019;14:482\u2013517. https:\/\/doi.org\/10.1038\/s41596-018-0103-9.","journal-title":"Nat Protoc"},{"key":"4246_CR20","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1158\/0008-5472.Can-15-1907","volume":"76","author":"X Zhang","year":"2016","unstructured":"Zhang X, et al. Single-cell sequencing for precise cancer research: progress and prospects. Cancer Res. 2016;76:1305\u201312. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-1907.","journal-title":"Cancer Res"},{"key":"4246_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41419-024-06522-y","volume":"15","author":"B Sheng","year":"2024","unstructured":"Sheng B, et al. Single-cell RNA sequencing of cervical exfoliated cells reveals potential biomarkers and cellular pathogenesis in cervical carcinogenesis. Cell Death Dis. 2024;15:130. https:\/\/doi.org\/10.1038\/s41419-024-06522-y.","journal-title":"Cell Death Dis"},{"key":"4246_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/mdr2.70004","volume":"1","author":"H Zhang","year":"2025","unstructured":"Zhang H, et al. <article-title update=\"added\">Optimized dynamic network biomarker deciphers a high\u2010resolution heterogeneity within thyroid cancer molecular subtypes. Med Research. 2025;1:10\u201331. https:\/\/doi.org\/10.1002\/mdr2.70004.","journal-title":"Med Research"},{"key":"4246_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012069","author":"P Zhang","year":"2025","unstructured":"Zhang P, et al. Mitochondrial pathway signature (MitoPS) predicts immunotherapy response and reveals NDUFB10 as a key immune regulator in lung adenocarcinoma. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-012069.","journal-title":"J Immunother Cancer"},{"key":"4246_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01548-2","volume":"15","author":"Z Xiao","year":"2024","unstructured":"Xiao Z, Liu X, Wang Y, Jiang S, Feng Y. Comprehensive analysis of single-cell and bulk RNA sequencing reveals postoperative progression markers for non-muscle invasive bladder cancer and predicts responses to immunotherapy. Discover oncology. 2024;15:649. https:\/\/doi.org\/10.1007\/s12672-024-01548-2.","journal-title":"Discover oncology"},{"key":"4246_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/path.5421","volume":"250","author":"H Gala","year":"2020","unstructured":"Gala H, Tomlinson I. The use of Mendelian randomisation to identify causal cancer risk factors: promise and limitations. J Pathol. 2020;250:541\u201354. https:\/\/doi.org\/10.1002\/path.5421.","journal-title":"J Pathol"},{"key":"4246_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103231","volume":"146","author":"J Li","year":"2024","unstructured":"Li J, Cheng C, Zhang J. Autoimmune diseases and the risk of bladder cancer: a Mendelian randomization analysis. J Autoimmun. 2024;146:103231. https:\/\/doi.org\/10.1016\/j.jaut.2024.103231.","journal-title":"J Autoimmun"},{"key":"4246_CR27","doi-asserted-by":"publisher","first-page":"e1003897","DOI":"10.1371\/journal.pmed.1003897","volume":"19","author":"J Yarmolinsky","year":"2022","unstructured":"Yarmolinsky J, et al. Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: a Mendelian randomization analysis. PLoS Med. 2022;19:e1003897. https:\/\/doi.org\/10.1371\/journal.pmed.1003897.","journal-title":"PLoS Med"},{"key":"4246_CR28","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1681\/asn.0000000000000434","volume":"35","author":"A Khan","year":"2024","unstructured":"Khan A, Lim TY, Sanna-Cherchi S. Mendelian randomization unveils drug targets for IgA nephropathy. J Am Soc Nephrol. 2024;35:988\u201391. https:\/\/doi.org\/10.1681\/asn.0000000000000434.","journal-title":"J Am Soc Nephrol"},{"key":"4246_CR29","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1093\/brain\/awad070","volume":"146","author":"J Lin","year":"2023","unstructured":"Lin J, Zhou J, Xu Y. Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis. Brain. 2023;146:3364\u201372. https:\/\/doi.org\/10.1093\/brain\/awad070.","journal-title":"Brain"},{"key":"4246_CR30","doi-asserted-by":"publisher","unstructured":"Ke X et al. Cloud-Based GWAS Platform: An Innovative Solution for Efficient Acquisition and Analysis of Genomic Data. n\/a. https:\/\/doi.org\/10.1002\/mdr2.70040","DOI":"10.1002\/mdr2.70040"},{"key":"4246_CR31","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","volume":"53","author":"U V\u00f5sa","year":"2021","unstructured":"V\u00f5sa U, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53:1300\u201310. https:\/\/doi.org\/10.1038\/s41588-021-00913-z.","journal-title":"Nat Genet"},{"key":"4246_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12931-024-02848-5","volume":"25","author":"Z Liu","year":"2024","unstructured":"Liu Z, et al. Identifying potential drug targets for idiopathic pulmonary fibrosis: a Mendelian randomization study based on the druggable genes. Respir Res. 2024;25:217. https:\/\/doi.org\/10.1186\/s12931-024-02848-5.","journal-title":"Respir Res"},{"key":"4246_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1302\/2046-3758.143.Bjr-2024-0207.R1","volume":"14","author":"XW Zhu","year":"2025","unstructured":"Zhu XW, et al. Evaluation of the causal relationship between 28 circulating biomarkers and osteoarthritis: a bidirectional Mendelian randomization study. Bone Joint Res. 2025;14:259\u201369. https:\/\/doi.org\/10.1302\/2046-3758.143.Bjr-2024-0207.R1.","journal-title":"Bone Joint Res"},{"key":"4246_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70172","volume":"31","author":"J Shi","year":"2025","unstructured":"Shi J, et al. Integrated Mendelian Randomization and Single-Cell Transcriptomics Analysis Identifies Critical Blood Biomarkers and Potential Mechanisms in Epilepsy. CNS Neurosci Ther. 2025;31:e70172. https:\/\/doi.org\/10.1111\/cns.70172.","journal-title":"CNS Neurosci Ther"},{"key":"4246_CR35","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","volume":"52","author":"V Orr\u00f9","year":"2020","unstructured":"Orr\u00f9 V, et al. Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat Genet. 2020;52:1036\u201345. https:\/\/doi.org\/10.1038\/s41588-020-0684-4.","journal-title":"Nat Genet"},{"key":"4246_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102530","volume":"115","author":"CM Ascione","year":"2023","unstructured":"Ascione CM, et al. Role of FGFR3 in bladder cancer: treatment landscape and future challenges. Cancer Treat Rev. 2023;115:102530. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102530.","journal-title":"Cancer Treat Rev"},{"key":"4246_CR37","first-page":"655","volume":"21","author":"TH Ecke","year":"2008","unstructured":"Ecke TH, Sachs MD, Lenk SV, Loening SA, Schlechte HH. TP53 gene mutations as an independent marker for urinary bladder cancer progression. Int J Mol Med. 2008;21:655\u201361.","journal-title":"Int J Mol Med"},{"key":"4246_CR38","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/ijc.33794","volume":"149","author":"H Lai","year":"2021","unstructured":"Lai H, et al. Single-cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer. Int J Cancer. 2021;149:2099\u2013115. https:\/\/doi.org\/10.1002\/ijc.33794.","journal-title":"Int J Cancer"},{"key":"4246_CR39","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ng2013","volume":"39","author":"GC Scheper","year":"2007","unstructured":"Scheper GC, et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet. 2007;39:534\u20139. https:\/\/doi.org\/10.1038\/ng2013.","journal-title":"Nat Genet"},{"key":"4246_CR40","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-452","volume":"9","author":"L Yang","year":"2021","unstructured":"Yang L, et al. Development and validation of a prediction model for lung adenocarcinoma based on RNA-binding protein. Ann Transl Med. 2021;9:474. https:\/\/doi.org\/10.21037\/atm-21-452.","journal-title":"Ann Transl Med"},{"key":"4246_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41598-021-03645-6","volume":"12","author":"N Sun","year":"2022","unstructured":"Sun N, et al. A novel 14-gene signature for overall survival in lung adenocarcinoma based on the bayesian hierarchical Cox proportional hazards model. Sci Rep. 2022;12:27. https:\/\/doi.org\/10.1038\/s41598-021-03645-6.","journal-title":"Sci Rep"},{"key":"4246_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04454-3","volume":"21","author":"XS Liu","year":"2023","unstructured":"Liu XS, et al. DARS2 overexpression is associated with PET\/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma. J Transl Med. 2023;21:574. https:\/\/doi.org\/10.1186\/s12967-023-04454-3.","journal-title":"J Transl Med"},{"key":"4246_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1301945","volume":"14","author":"H Yang","year":"2023","unstructured":"Yang H, et al. Prognostic biomarker DARS2 correlated with immune infiltrates in bladder tumor. Front Immunol. 2023;14:1301945. https:\/\/doi.org\/10.3389\/fimmu.2023.1301945.","journal-title":"Front Immunol"},{"key":"4246_CR44","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.7150\/ijbs.107632","volume":"21","author":"D Li","year":"2025","unstructured":"Li D, et al. DARS2 promotes bladder cancer progression by enhancing PINK1-mediated mitophagy. Int J Biol Sci. 2025;21:1530\u201344. https:\/\/doi.org\/10.7150\/ijbs.107632.","journal-title":"Int J Biol Sci"},{"key":"4246_CR45","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X2024e13780","volume":"57","author":"B Liang","year":"2024","unstructured":"Liang B, Li L, He C, Wang M, Mao G. MRTO4 acts as an independent prognostic and immunological biomarker and is correlated with tumor microenvironment in hepatocellular carcinoma. Braz J Med Biol Res. 2024;57:e13780. https:\/\/doi.org\/10.1590\/1414-431X2024e13780.","journal-title":"Braz J Med Biol Res"},{"key":"4246_CR46","doi-asserted-by":"publisher","DOI":"10.12659\/msm.944685","volume":"30","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Huang Y, Li W, Cheng H. MRTO4 enhances glycolysis to facilitate HCC progression by inhibiting ALDOB. Med Sci Monit. 2024;30:e944685. https:\/\/doi.org\/10.12659\/msm.944685.","journal-title":"Med Sci Monit"},{"key":"4246_CR47","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41401-024-01236-5","volume":"45","author":"BB Hao","year":"2024","unstructured":"Hao BB, et al. Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations. Acta Pharmacol Sin. 2024;45:1305\u201315. https:\/\/doi.org\/10.1038\/s41401-024-01236-5.","journal-title":"Acta Pharmacol Sin"},{"key":"4246_CR48","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11239-018-1662-x","volume":"46","author":"K Sundquist","year":"2018","unstructured":"Sundquist K, et al. Polymorphisms in PARK2 and MRPL37 are associated with higher risk of recurrent venous thromboembolism in a sex-specific manner. J Thromb Thrombolysis. 2018;46:154\u201365. https:\/\/doi.org\/10.1007\/s11239-018-1662-x.","journal-title":"J Thromb Thrombolysis"},{"key":"4246_CR49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12094-023-03269-4","volume":"26","author":"JW Zhao","year":"2024","unstructured":"Zhao JW, et al. The role of the mitochondrial ribosomal protein family in detecting hepatocellular carcinoma and predicting prognosis, immune features, and drug sensitivity. Clin Translational Oncology: Official Publication Federation Span Oncol Soc Natl Cancer Inst Mexico. 2024;26:496\u2013514. https:\/\/doi.org\/10.1007\/s12094-023-03269-4.","journal-title":"Clin Translational Oncology: Official Publication Federation Span Oncol Soc Natl Cancer Inst Mexico"},{"key":"4246_CR50","doi-asserted-by":"publisher","first-page":"28491","DOI":"10.1038\/s41598-024-78729-0","volume":"14","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Construction of molecular subtype and prognostic model for gastric cancer based on nucleus-encoded mitochondrial genes. Sci Rep. 2024;14:28491. https:\/\/doi.org\/10.1038\/s41598-024-78729-0.","journal-title":"Sci Rep"},{"key":"4246_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.omto.2021.09.002","volume":"23","author":"R Vishnubalaji","year":"2021","unstructured":"Vishnubalaji R, Alajez NM. Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq. Mol Ther Oncolytics. 2021;23:151\u201362. https:\/\/doi.org\/10.1016\/j.omto.2021.09.002.","journal-title":"Mol Ther Oncolytics"},{"key":"4246_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-024-02291-7","volume":"75","author":"W Du","year":"2025","unstructured":"Du W, et al. Precision prediction of Alzheimer\u2019s disease: integrating mitochondrial energy metabolism and immunological insights. J Mol Neurosci. 2025;75:5. https:\/\/doi.org\/10.1007\/s12031-024-02291-7.","journal-title":"J Mol Neurosci"},{"key":"4246_CR53","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41419-021-04370-8","volume":"12","author":"S Min","year":"2021","unstructured":"Min S, et al. MRPS31 loss is a key driver of mitochondrial deregulation and hepatocellular carcinoma aggressiveness. Cell Death Dis. 2021;12:1076. https:\/\/doi.org\/10.1038\/s41419-021-04370-8.","journal-title":"Cell Death Dis"},{"key":"4246_CR54","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1023\/b:rubi.0000043788.86955.ea","volume":"30","author":"EV Levshenkova","year":"2004","unstructured":"Levshenkova EV, et al. [The structure and specific features of the cDNA expression of the human gene MRPL37]. Bioorg Khim. 2004;30:499\u2013506. https:\/\/doi.org\/10.1023\/b:rubi.0000043788.86955.ea.","journal-title":"Bioorg Khim"},{"key":"4246_CR55","doi-asserted-by":"publisher","first-page":"101896","DOI":"10.1016\/j.tranon.2024.101896","volume":"42","author":"Z Liu","year":"2024","unstructured":"Liu Z, et al. Mitochondria-related chemoradiotherapy resistance genes-based machine learning model associated with immune cell infiltration on the prognosis of esophageal cancer and its value in pan-cancer. Transl Oncol. 2024;42:101896. https:\/\/doi.org\/10.1016\/j.tranon.2024.101896.","journal-title":"Transl Oncol"},{"key":"4246_CR56","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh DY, et al. Intratumoral CD4(+) T cells mediate Anti-tumor cytotoxicity in human bladder cancer. Cell. 2020;181:1612\u2013e16251613. https:\/\/doi.org\/10.1016\/j.cell.2020.05.017.","journal-title":"Cell"},{"key":"4246_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","volume":"19","author":"TL Murphy","year":"2022","unstructured":"Murphy TL, Murphy KM. Dendritic cells in cancer immunology. Cell Mol Immunol. 2022;19:3\u201313. https:\/\/doi.org\/10.1038\/s41423-021-00741-5.","journal-title":"Cell Mol Immunol"},{"key":"4246_CR58","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.1158\/1078-0432.Ccr-08-1364","volume":"14","author":"CJ Farrell","year":"2008","unstructured":"Farrell CJ, et al. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res. 2008;14:7711\u20136. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-1364.","journal-title":"Clin Cancer Res"},{"key":"4246_CR59","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv LB. IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18:545\u201358. https:\/\/doi.org\/10.1038\/s41577-018-0029-z.","journal-title":"Nat Rev Immunol"},{"key":"4246_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263. https:\/\/doi.org\/10.1038\/s41392-021-00658-5.","journal-title":"Signal Transduct Target Ther"},{"key":"4246_CR61","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860\u20137. https:\/\/doi.org\/10.1038\/nature01322.","journal-title":"Nature"},{"key":"4246_CR62","first-page":"217","volume":"16","author":"E Shacter","year":"2002","unstructured":"Shacter E, Weitzman SA, J. O Chronic Inflamm Cancer. 2002;16:217\u201326. 229; discussion 230.","journal-title":"O Chronic Inflamm Cancer"},{"key":"4246_CR63","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41571-020-00459-9","volume":"18","author":"J Hou","year":"2021","unstructured":"Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat Rev Clin Oncol. 2021;18:261\u201379. https:\/\/doi.org\/10.1038\/s41571-020-00459-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"4246_CR64","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54:859\u201374. https:\/\/doi.org\/10.1016\/j.immuni.2021.01.012.","journal-title":"Immunity"},{"key":"4246_CR65","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metabol. 2016;23:27\u201347. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.006.","journal-title":"Cell Metabol"},{"key":"4246_CR66","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.cell.2020.07.039","volume":"182","author":"F Bonnay","year":"2020","unstructured":"Bonnay F, et al. Oxidative metabolism drives immortalization of neural stem cells during tumorigenesis. Cell. 2020;182:1490\u2013e15071419. https:\/\/doi.org\/10.1016\/j.cell.2020.07.039.","journal-title":"Cell"},{"key":"4246_CR67","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2006.07.014","volume":"16","author":"CV Dang","year":"2006","unstructured":"Dang CV, et al. The c-Myc target gene network. Semin Cancer Biol. 2006;16:253\u201364. https:\/\/doi.org\/10.1016\/j.semcancer.2006.07.014.","journal-title":"Semin Cancer Biol"},{"key":"4246_CR68","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227\u201331. https:\/\/doi.org\/10.1126\/science.aac9935.","journal-title":"Science"},{"key":"4246_CR69","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.gie.2019.12.049","volume":"91","author":"R Hashimoto","year":"2020","unstructured":"Hashimoto R, et al. Artificial intelligence using convolutional neural networks for real-time detection of early esophageal neoplasia in barrett\u2019s esophagus (with video). Gastrointest Endosc. 2020;91:1264\u2013e12711261. https:\/\/doi.org\/10.1016\/j.gie.2019.12.049.","journal-title":"Gastrointest Endosc"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04246-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04246-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04246-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:54:43Z","timestamp":1768366483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04246-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4246"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04246-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used in this study were obtained from the TCGA, GEO, FinnGen, and IEU Open GWAS databases. These databases are publicly available and do not require additional consent for secondary analyses.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final version of the manuscript and consent to its publication. The manuscript has not been published previously and is not under consideration for publication elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}